Logo image of STOK

STOKE THERAPEUTICS INC (STOK) Stock Fundamental Analysis

NASDAQ:STOK - Nasdaq - US86150R1077 - Common Stock - Currency: USD

11.75  -0.31 (-2.57%)

After market: 11.76 +0.01 (+0.09%)

Fundamental Rating

5

Taking everything into account, STOK scores 5 out of 10 in our fundamental rating. STOK was compared to 558 industry peers in the Biotechnology industry. STOK is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. STOK has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year STOK was profitable.
STOK had a positive operating cash flow in the past year.
STOK had negative earnings in each of the past 5 years.
In the past 5 years STOK always reported negative operating cash flow.
STOK Yearly Net Income VS EBIT VS OCF VS FCFSTOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

STOK has a Return On Assets of 12.36%. This is amongst the best in the industry. STOK outperforms 95.70% of its industry peers.
STOK has a better Return On Equity (14.36%) than 95.16% of its industry peers.
STOK has a better Return On Invested Capital (8.34%) than 94.27% of its industry peers.
Industry RankSector Rank
ROA 12.36%
ROE 14.36%
ROIC 8.34%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
STOK Yearly ROA, ROE, ROICSTOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

STOK has a better Profit Margin (26.33%) than 96.24% of its industry peers.
The Operating Margin of STOK (20.03%) is better than 95.52% of its industry peers.
Industry RankSector Rank
OM 20.03%
PM (TTM) 26.33%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STOK Yearly Profit, Operating, Gross MarginsSTOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

8

2. Health

2.1 Basic Checks

STOK has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
STOK has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, STOK has more shares outstanding
STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STOK Yearly Shares OutstandingSTOK Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STOK Yearly Total Debt VS Total AssetsSTOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

STOK has an Altman-Z score of 7.41. This indicates that STOK is financially healthy and has little risk of bankruptcy at the moment.
STOK has a better Altman-Z score (7.41) than 83.33% of its industry peers.
STOK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.41
ROIC/WACC0.86
WACC9.68%
STOK Yearly LT Debt VS Equity VS FCFSTOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 8.41 indicates that STOK has no problem at all paying its short term obligations.
STOK's Current ratio of 8.41 is fine compared to the rest of the industry. STOK outperforms 72.04% of its industry peers.
STOK has a Quick Ratio of 8.41. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
STOK has a Quick ratio of 8.41. This is in the better half of the industry: STOK outperforms 72.04% of its industry peers.
Industry RankSector Rank
Current Ratio 8.41
Quick Ratio 8.41
STOK Yearly Current Assets VS Current LiabilitesSTOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

STOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 136.04%, which is quite impressive.
Looking at the last year, STOK shows a very strong growth in Revenue. The Revenue has grown by 2332.57%.
EPS 1Y (TTM)136.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%447.37%
Revenue 1Y (TTM)2332.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3661.12%

3.2 Future

STOK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.68% yearly.
Based on estimates for the next years, STOK will show a very strong growth in Revenue. The Revenue will grow by 64.04% on average per year.
EPS Next Y103.64%
EPS Next 2Y-29.76%
EPS Next 3Y-10.68%
EPS Next 5Y15.68%
Revenue Next Year840.72%
Revenue Next 2Y45.06%
Revenue Next 3Y35.5%
Revenue Next 5Y64.04%

3.3 Evolution

STOK Yearly Revenue VS EstimatesSTOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
STOK Yearly EPS VS EstimatesSTOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 13.51 indicates a correct valuation of STOK.
Based on the Price/Earnings ratio, STOK is valued cheaper than 96.06% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.19. STOK is valued rather cheaply when compared to this.
STOK is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 13.51
Fwd PE N/A
STOK Price Earnings VS Forward Price EarningsSTOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of STOK indicates a rather cheap valuation: STOK is cheaper than 98.92% of the companies listed in the same industry.
STOK's Price/Free Cash Flow ratio is rather cheap when compared to the industry. STOK is cheaper than 97.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.27
EV/EBITDA 5.42
STOK Per share dataSTOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
STOK's earnings are expected to decrease with -10.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.13
PEG (5Y)N/A
EPS Next 2Y-29.76%
EPS Next 3Y-10.68%

More info and screens

0

5. Dividend

5.1 Amount

STOK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STOKE THERAPEUTICS INC

NASDAQ:STOK (7/15/2025, 8:00:00 PM)

After market: 11.76 +0.01 (+0.09%)

11.75

-0.31 (-2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-05 2025-08-05
Inst Owners105.26%
Inst Owner Change0%
Ins Owners4.36%
Ins Owner Change4.55%
Market Cap641.55M
Analysts83.75
Price Target22.82 (94.21%)
Short Float %22.15%
Short Ratio18.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)312.62%
Min EPS beat(2)66.58%
Max EPS beat(2)558.67%
EPS beat(4)4
Avg EPS beat(4)164.56%
Min EPS beat(4)13.51%
Max EPS beat(4)558.67%
EPS beat(8)7
Avg EPS beat(8)85.13%
EPS beat(12)11
Avg EPS beat(12)60.94%
EPS beat(16)11
Avg EPS beat(16)26.37%
Revenue beat(2)2
Avg Revenue beat(2)1046.03%
Min Revenue beat(2)417.96%
Max Revenue beat(2)1674.1%
Revenue beat(4)4
Avg Revenue beat(4)545.19%
Min Revenue beat(4)43.23%
Max Revenue beat(4)1674.1%
Revenue beat(8)6
Avg Revenue beat(8)252.14%
Revenue beat(12)10
Avg Revenue beat(12)182.11%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-26.31%
EPS NY rev (1m)103.65%
EPS NY rev (3m)102.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)274.69%
Valuation
Industry RankSector Rank
PE 13.51
Fwd PE N/A
P/S 3.36
P/FCF 9.27
P/OCF 9.23
P/B 1.83
P/tB 1.83
EV/EBITDA 5.42
EPS(TTM)0.87
EY7.4%
EPS(NY)-2.83
Fwd EYN/A
FCF(TTM)1.27
FCFY10.79%
OCF(TTM)1.27
OCFY10.84%
SpS3.5
BVpS6.41
TBVpS6.41
PEG (NY)0.13
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.36%
ROE 14.36%
ROCE 10.56%
ROIC 8.34%
ROICexc 619.21%
ROICexgc 619.21%
OM 20.03%
PM (TTM) 26.33%
GM N/A
FCFM 36.25%
ROA(3y)-39.36%
ROA(5y)-34.31%
ROE(3y)-53.05%
ROE(5y)-43.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 16.4%
Cap/Sales 0.18%
Interest Coverage 250
Cash Conversion 172.42%
Profit Quality 137.65%
Current Ratio 8.41
Quick Ratio 8.41
Altman-Z 7.41
F-Score8
WACC9.68%
ROIC/WACC0.86
Cap/Depr(3y)110.09%
Cap/Depr(5y)114.39%
Cap/Sales(3y)16.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%447.37%
EPS Next Y103.64%
EPS Next 2Y-29.76%
EPS Next 3Y-10.68%
EPS Next 5Y15.68%
Revenue 1Y (TTM)2332.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3661.12%
Revenue Next Year840.72%
Revenue Next 2Y45.06%
Revenue Next 3Y35.5%
Revenue Next 5Y64.04%
EBIT growth 1Y132.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.82%
EBIT Next 3Y10.49%
EBIT Next 5Y17.28%
FCF growth 1Y177.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.13%
OCF growth 3YN/A
OCF growth 5YN/A